Pharma Industry News

Opinion: Fecal transplants are saving lives — but are now at risk

Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection. I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced.

Soon I was in a hazmat suit blenderizing stool and performing my first (subsequently named) fecal microbiota transplant, or FMT. My patient was cured, and I began two decades of care of thousands of patients with refractory C. difficile infection, a therapy that might seem counterintuitive (stool as medicine?) but in fact, is quite biologically rational: C. difficile thrives in a disturbed, damaged colonic microbiome. The transplant repairs the damage so the bacteria no longer thrive.
Read the rest…

Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection. I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced.

Soon I was in a hazmat suit blenderizing stool and performing my first (subsequently named) fecal microbiota transplant, or FMT. My patient was cured, and I began two decades of care of thousands of patients with refractory C. difficile infection, a therapy that might seem counterintuitive (stool as medicine?) but in fact, is quite biologically rational: C. difficile thrives in a disturbed, damaged colonic microbiome. The transplant repairs the damage so the bacteria no longer thrive.

Read the rest…

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]